High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience
High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience
复制标题
DOI：
10.1007/s12149-020-01514-2
复制
发表时间：
2020-08
影响因子：
2.6
通讯作者：
H. Wakabayashi;Daiki Kayano;A. Inaki;Raita Araki;Rie Kuroda;Y. Ikawa;Toshihiro Fujiki;Norihito Akatani;Takafumi Yamase;Satoru Watanabe;T. Hiromasa;Yuji Kunita;H. Mori;Shintaro Saito;R. Nishimura;T. Wada;S. Kinuya
中科院分区：
文献类型：
--
作者：
H. Wakabayashi;Daiki Kayano;A. Inaki;Raita Araki;Rie Kuroda;Y. Ikawa;Toshihiro Fujiki;Norihito Akatani;Takafumi Yamase;Satoru Watanabe;T. Hiromasa;Yuji Kunita;H. Mori;Shintaro Saito;R. Nishimura;T. Wada;S. Kinuya
目的尽管采用现代多学科治疗，复发性神经母细胞瘤儿童的预后仍较差。复发性神经母细胞瘤需要新颖且更有效的治疗策略。我们回顾性研究了高剂量 131I-间碘苄基胍 (131I-mIBG) 巩固治疗在复发性神经母细胞瘤或神经节神经母细胞瘤患者中的效用，经诊断性 123I-mIBG 闪烁扫描证实，对诱导治疗有完全缓解 (CR)。 方法 2009 年 12 月至 2014 年 12 月至 2014 年，5 名复发性神经母细胞瘤患者和 1 名复发性神经母细胞瘤患者神经节神经母细胞瘤接受高剂量131I-mIBG治疗。通过Kaplan-Meier法分析131I-mIBG治疗后五年的总体生存率和无进展生存率。结果在随访期间，三名儿童没有表现出疾病复发的迹象，而三名儿童死亡。一名没有复发的儿童死于移植后副作用，两名复发的儿童因肿瘤进展而死亡。 131I-mIBG治疗后5年无进展生存率和总生存率分别为44%和67%。结论2ndCR患者接受高剂量131I-mIBG巩固治疗显示出良好的总生存率和无进展生存率。虽然必须考虑辐射暴露的风险，但作为巩固治疗的高剂量 131 I-mIBG 治疗需要进一步研究。
ObjectiveChildren with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose131I-meta-iodo-benzyl-guanidine (131I-mIBG) in relapsed neuroblastoma or ganglioneuroblastoma patients with complete response (CR) to induction therapy as demonstrated by diagnostic123I-mIBG scintigraphy.MethodsBetween December 2009 and 2014, five patients with relapsed neuroblastoma and one with relapsed ganglioneuroblastoma received high-dose131I-mIBG therapy. Overall and progression-free survival rates at five years after131I-mIBG therapy were analyzed by the Kaplan–Meier method.ResultsDuring follow-up, three children showed no signs of disease relapse, whereas three died. One child without a relapse died from post-transplant side effects, and two children with a relapse died owing to tumor progression. The 5-year progression-free and overall survival rates after131I-mIBG therapy were 44% and 67%, respectively.ConclusionsConsolidation therapy with high-dose131I-mIBG for patients with 2ndCR showed good overall and progression-free survival. While the risks of radiation exposure must be considered, high-dose131I-mIBG therapy as consolidation therapy needs to be further investigated.